Article info

other Versions

PDF

Extended report
A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab

Authors

  1. Correspondence to Dr Primal Kaur, Biosimilars Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA; pkaur{at}amgen.com
View Full Text

Citation

Kaur P, Chow V, Zhang N, et al
A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab

Publication history

  • Received 17 November 2015
  • Revised 28 June 2016
  • Accepted 29 June 2016
  • Published online 27 July 2016.

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.